恒瑞医药：SHR7280片药品上市许可申请获受理

Core Viewpoint - Heng Rui Medicine has received acceptance notification from the National Medical Products Administration for its drug application of SHR7280 tablets, marking a significant step in the approval process for a new oral GnRH receptor antagonist [1] Company Summary - The SHR7280 tablets are designed as an oral small molecule GnRH receptor antagonist, which can block the binding of endogenous GnRH to GnRH receptors, thereby inhibiting the synthesis and release of luteinizing hormone (LH) and other gonadotropins [1] - This drug is intended for use in controlled ovarian hyperstimulation treatment within assisted reproductive technology [1] Industry Summary - Currently, there are no approved oral GnRH antagonists in the domestic and international assisted reproduction field, indicating a potential market opportunity for SHR7280 tablets [1]